160 related articles for article (PubMed ID: 26612216)
1. Active Surveillance: Pathologic and Clinical Variables Associated with Outcome.
Pomerantz M
Surg Pathol Clin; 2015 Dec; 8(4):581-5. PubMed ID: 26612216
[TBL] [Abstract][Full Text] [Related]
2. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
4. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
5. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance for prostate cancer: when to recommend delayed intervention.
Babaian KN
Asian J Androl; 2015; 17(6):885-7; discussion 886-7. PubMed ID: 26178391
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
[No Abstract] [Full Text] [Related]
9. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer - active surveillance as a management option.
Yaxley J; Yaxley J; Gardiner R; Yaxley W
Aust Fam Physician; 2013; 42(1-2):74-6. PubMed ID: 23529468
[TBL] [Abstract][Full Text] [Related]
11. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
12. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
van der Poel H; Klotz L; Andriole G; Azzouzi AR; Bjartell A; Cussenot O; Hamdy F; Graefen M; Palma P; Rivera AR; Stief CG
World J Urol; 2015 Jul; 33(7):907-16. PubMed ID: 26037891
[TBL] [Abstract][Full Text] [Related]
13. Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?
Gandaglia G; Giannarini G; Suardi N; Montorsi F; Briganti A
Eur Urol; 2014 Aug; 66(2):186-7. PubMed ID: 24836154
[TBL] [Abstract][Full Text] [Related]
14. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance monitoring: the role of novel biomarkers and imaging.
Ward JF; Eggener SE
Asian J Androl; 2015; 17(6):882-4; discussion 883. PubMed ID: 26112488
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
Ferlicot S
Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
[No Abstract] [Full Text] [Related]
17. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
Thomsen FB
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
[TBL] [Abstract][Full Text] [Related]
19. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance: patient selection.
Klotz L
Curr Opin Urol; 2013 May; 23(3):239-44. PubMed ID: 23548978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
